GLP-1 Receptor Agonist Peptide Market Trends, Brand Comparisons, and Product Technology Analysis
Published: July 12, 2026 23:26
Author: Chiara Conti
Abstract: The GLP-1 receptor agonist peptide market is projected to exceed $56 billion by 2030, driven by obesity and diabetes prevalence. Key brands (semaglutide, tirzepatide, liraglutide) show distinct efficacy and safety profiles. Product technology analysis reveals advantages in glycemic control and weight loss, but gastrointestinal side effects and cold-chain logistics remain challenges. Market trends favor oral formulations and dual/triple agonists. Selection criteria prioritize purity (>98%), GMP certification, and cold-chain compliance. Industry growth is supported by expanding indications (NASH, cardiovascular) and biosimilar entry.